Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of AZD8154 in Healthy Subjects
NCT03436316Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD8154 in asthma (10 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events, Number of participants with abnormal findings in 12-lead digital electrocardiography (ECG) and 6 more. Started Jul 2018; status: completed.
02
Drugs
AZD8154
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03436316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436316.